Bellon G, Ounis I
Centre Hospitalier Lyon Sud, Sainte-Eugénie, Pierre-Bénite.
Ann Pediatr (Paris). 1990 Oct;37(8):535-40.
Biostim is an immunomodulating agent of biologic origin indicated for the prophylactic treatment of recurrent respiratory tract infections in adults and children over one year of age. It has been proved effective by double-blind placebo-controlled trials. This study was undertaken to evaluate the value and tolerance of Biostim in a large number of patients under the conditions of actual use. Three thousand and eight patients were included in the study. At inclusion, 93.7% of patients had a history of recurrent ENT infections (6.27 +/- 3.04 episodes during the previous year). After three months follow-up, results were considered good by the investigator in 75.8% of cases; 75.3% of the children had either no infection or only one infection during the three months follow-up. Results were not influenced by age and/or a history of allergy.
必思添是一种生物源免疫调节剂，适用于预防一岁以上成人和儿童复发性呼吸道感染。双盲安慰剂对照试验已证明其有效。本研究旨在评估必思添在实际使用条件下对大量患者的疗效和耐受性。该研究纳入了3008名患者。纳入研究时，93.7%的患者有耳鼻喉反复感染史（前一年6.27±3.04次发作）。经过三个月的随访，研究者认为75.8%的病例结果良好；75.3%的儿童在三个月随访期间未发生感染或仅发生一次感染。结果不受年龄和/或过敏史的影响。
